Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0

Boers, Maarten; Kirwan, John R.; Wells, George A.; Beaton, Dorcas; Gossec, Laure; D'Agostino, Maria Antonietta; Conaghan, Philip G.; Bingham, Clifton O.; Brooks, Peter; Landewé, Robert; March, Lyn; Simon, Lee S.; Singh, Jasvinder A.; Strand, Vibeke; Tugwell, Peter

doi:10.1016/j.jclinepi.2013.11.013

Cited by 673 publications

(757 citation statements)

References 21 publications

Supporting

Mentioning

749

Contrasting

Order By: Relevance

“…Indeed, there have been recent proposals for 'core adverse events' to be considered in formulating core outcome measurement sets in some disease areas [ 5 ]. It may even be possible to meta-analyse across different indications [ 6 ].…”

Section: Glucocorticoid-related Adverse Effectsmentioning

confidence: 99%

The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

et al. 2015

View full text Add to dashboard Cite

Glucocorticoids are often required for adequate control of inflammation in many serious inflammatory diseases; common indications for long-term treatment include polymyalgia rheumatica, giant cell arteritis, asthma and chronic obstructive pulmonary disease. Long-term glucocorticoid therapy is, however, associated with many adverse effects involving skin, gastrointestinal, eye, skeletal muscle, bone, adrenal, cardio-metabolic and neuropsychiatric systems. This balance between benefits and risks of glucocorticoids is important for clinical practice and glucocorticoid-related adverse effects can significantly impair health-related quality of life. Understanding the nature and mechanisms of glucocorticoid-related adverse effects may inform how patients are monitored for toxicity and identify those groups, such as older people, that may need closer monitoring. For clinical trials in diseases commonly treated with glucocorticoids, standardised measurement of glucocorticoid-related adverse effects would facilitate future evidence synthesis and meta-analysis.

show abstract

Section: Glucocorticoid-related Adverse Effectsmentioning

confidence: 99%

The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…OMERACT advocates that at least one domain is chosen from each of four "Core Areas": pathophysiological manifestations; life impact; death; and resource use [11]. Instruments are subsequently selected to cover each Core Domain.…”

Section: Methodsmentioning

confidence: 99%

Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis

et al. 2016

View full text Add to dashboard Cite

Objectives: To obtain consensus on minimum data items for an observational cohort study in rheumatoid arthritis (RA) in the UK and to make available the process for similar studies and other rheumatic conditions.Methods: Individuals with a diverse range of expertise and backgrounds were invited to participate in a process to propose a minimal core dataset (MCD) for research studies, items for inclusion into a MCD. Workshops were undertaken for two essential items which required further exploration: work/social participation and co-morbidity. Conclusions:Consensus for proposed minimal data items for long-term observational cohort studies of RA in the UK posed novel challenges and opportunities, and was largely successful.Further work is needed to select instruments for two important items and to achieve compatibility with other UK national initiatives, and more widely across Europe.

show abstract

“…4 In contrast, biologic measures have not been incorporated at the bedside, despite evidence demonstrating that DNA, gene and protein expression and cellular immunophenotyping profiles help stratify patients and define homogeneous patient groups and point to molecular determinants of susceptibility and outcome in many rheumatologic diseases including childhood arthritis and rheumatic diseases. 3,5,6 Additional challenges arise when research is focused on rare diseases.…”

Section: Introductionmentioning

confidence: 99%

Enhancing translational research in paediatric rheumatology through standardization

et al. 2016

View full text Add to dashboard Cite

Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0

Abstract: The OMERACT Filter 2.0 explicitly describes a comprehensive conceptual framework and a recommended process to develop core outcome measurement sets for rheumatology likely to be useful as a template in other areas of health care.

Cited by 673 publications

References 21 publications

The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis

Enhancing translational research in paediatric rheumatology through standardization

Contact Info

Product

Resources

About